| Product Name | Revefenacin - API |
| Product Code | DA-R135-a |
| Chemical name | Revefenacin |
| Synonyms | Carbamic acid, N-[1,1'-biphenyl]-2-yl-, 1-[2-[[4-[[4-(aminocarbonyl)-1-piperidinyl]methyl]benzoyl]methylamino]ethyl]-4-piperidinyl ester; 1-[2-(1-{4-[(4-Carbamoylpiperidin-1-yl)methyl]phenyl}-N-methylformamido)ethyl]piperidin-4-yl N-{[1,1'-biphenyl]-2-yl}carbamate; |
| Impurity | NA |
| CAS Number | 864750-70-9 |
| Alternate CAS # | NA |
| Molecular form | C35H43N5O4 |
| Appearance | NA |
| Melting Point | NA |
| Mol. Weight | 597.76 |
| Storage | 2-8°C Refrigerator |
| Solubility | NA |
| Stability | NA |
| Category | impurities,metabolites,pharmaceutical standards,intermediates,Fine Chemicals |
| Boiling Point | NA |
| Applications | Revefenacin is a novel biphenyl carbamate tertiary amine agent that belongs to the family of the long-acting muscarinic antagonists (LABA). The labile primary amide in the structure produces a "soft-drug" site that allows rapid systemic clearance and minimizing of the systemically mediated adverse reactions. The LABA group falls into a parent category known as long-acting inhaled bronchodilators and this type of agents are recommended as a maintenance therapy for chronic obstructive pulmonary disease (COPD).1 From the LABA group, revefenacin is the first once-daily nebulized LAMA treatment.2 It was developed by Theravance Biopharma and FDA approved on November 9, 2018.8 |
| Dangerous Goods Info | NA |
| References | NA |
| Extra Notes | NA |
| Documents (MSDS) | No Data Available |
| Keywords | NA |
